Svensson Lars G, Kim Kyung-Hwan, Blackstone Eugene H, Alster Joan M, McCarthy Patrick M, Greenberg Roy K, Sabik Joseph F, D'Agostino Richard S, Lytle Bruce W, Cosgrove Delos M
Center for Aortic Surgery, Marfan Syndrome and Connective Tissue Disorders Clinic and Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Ohio 44195, USA.
Ann Thorac Surg. 2004 Jul;78(1):109-16; discussion 109-16. doi: 10.1016/j.athoracsur.2004.02.098.
The elephant trunk procedure is used for extensive aortic aneurysms. We evaluated its safety, newer indications, and influence of second-stage completion on survival.
Records were reviewed for 94 consecutive patients (age 67 +/- 11 years, 47% men) who underwent the procedure between November 1990 and February 2003. The trunk was implanted as an extension of the ascending aorta and arch graft in 83 of 94 (88.3%) patients, distal arch graft in 8 of 94 (8.5%) patients, and in 3 distal to the left subclavian artery (3 of 94 patients [3.2%]). Aortic dissection was present in 37 (39.4%) patients and Marfan syndrome was present in 7 (7.4%). Twenty-three were reoperations (24.5%). In 9 patients, the trunk procedure was adjunctive in preparation for the second operation. In 15 patients, the anastomosis was completed between the left subclavian and common carotid arteries. Coronary artery bypass was performed in 36 (38.4%) and aortic valve operation in 55 (58.5%; 20 root sparing repairs, 16 composite grafts and 19 replacements) patients.
There were two early 30-day in-hospital deaths (2.1%) and 5 permanent strokes (5.3%). Eleven died before the second-stage procedure. Forty-seven (57%) underwent second-stage procedures; 40 by thoracotomy and 7 by stent graft insertion, including 2 thoracoabdominal aneurysm repairs with visceral bypasses before stent grafting with 4 early deaths (8.5%). Five-year survival was 34% without a second-stage procedure versus 75% 3-year survival with it.
With a current total of 142 elephant trunk procedures, we found it is safe and should be used more with initial cardiac surgery before descending or thoracoabdominal aorta repair.
象鼻手术用于治疗广泛的主动脉瘤。我们评估了其安全性、新的适应证以及二期手术完成对生存率的影响。
回顾了1990年11月至2003年2月期间连续94例接受该手术患者(年龄67±11岁,47%为男性)的记录。94例患者中83例(88.3%)将人工血管作为升主动脉和主动脉弓移植物的延伸植入,8例(8.5%)植入远端主动脉弓移植物,3例(3.2%)植入至左锁骨下动脉远端。37例(39.4%)患者存在主动脉夹层,7例(7.4%)患者患有马凡综合征。23例(24.5%)为再次手术。9例患者的象鼻手术是为二期手术做准备的辅助手术。15例患者在左锁骨下动脉和颈总动脉之间完成了吻合。36例(38.4%)患者进行了冠状动脉旁路移植术,55例(58.5%;20例保留主动脉根部修复、16例复合移植物和19例置换)患者进行了主动脉瓣手术。
30天内有2例早期住院死亡(2.1%),5例永久性卒中(5.3%)。11例在二期手术前死亡。47例(57%)接受了二期手术;40例通过开胸手术,7例通过支架植入,其中包括2例胸腹主动脉瘤修复并在内脏旁路术前进行支架植入,有4例早期死亡(8.5%)。未进行二期手术的患者5年生存率为34%,进行二期手术的患者3年生存率为75%。
目前共有142例象鼻手术,我们发现该手术是安全的,并且在降主动脉或胸腹主动脉修复前应更多地与初次心脏手术联合使用。